Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:52:18 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Z:AZN - ASTRAZENECA PLC - https://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Z1.0180.00·181.990.1181.58-3.27-1.81,379.5248,45820,040183.25  183.44  180.55212.71  68.0819:43:2121:5215 min RT 2¢

Recent Trades - Last 10 of 20040
Time ETExPriceChangeVolume
19:43:21Z181.9415-3.01851
18:52:47Z181.06-3.9032
18:51:38Z181.10-3.8618
18:39:36Z182.14-2.821
18:34:56Z182.10-2.86100
18:23:26Z180.67-4.292
17:46:20Z180.9873-3.972752
17:17:39Z180.00-4.961
17:17:39Z180.00-4.962
17:17:33Z180.00-4.963

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-15 21:52U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
2026-05-14 07:00U:AZNNews ReleasePerioperative IMFINZI(TM) (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
2026-04-30 21:42U:AZNNews ReleaseTRUQAP(TM) (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
2026-04-29 19:00U:AZNNews ReleasePinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
2026-04-29 07:00U:AZNNews ReleaseAstraZeneca results: Q1 2026
2026-04-28 07:00U:AZNNews ReleaseBREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
2026-04-27 07:00U:AZNNews ReleaseSAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
2026-04-20 07:00U:AZNNews ReleaseTozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
2026-04-02 07:00U:AZNNews ReleaseIMFINZI(TM) (durvalumab) + IMJUDO(TM) (tremelimumab-actl) improves PFS in early liver cancer
2026-03-27 07:00U:AZNNews ReleaseTozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
2026-03-10 08:30U:AZNNews ReleaseAstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
2026-03-09 08:05U:AZNNews ReleaseKoselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1
2026-03-09 07:00U:AZNNews ReleaseENHERTU(TM) (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
2026-02-20 07:00U:AZNNews ReleaseCALQUENCE(TM) plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
2026-02-13 07:00U:AZNNews ReleasePositive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
2026-02-11 09:00U:AZNNews ReleaseAstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US
2026-02-10 07:00U:AZNNews ReleaseAstraZeneca results: FY and Q4 2025
2026-02-03 07:00U:AZNNews ReleaseDATROWAY(TM) (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
2026-02-02 07:00U:AZNNews ReleaseAstraZeneca begins trading on the New York Stock Exchange
2026-01-08 07:00U:AZNNews ReleaseRick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit